Who should not take PT-141 (Bremelanotide)?
Documented caution flags for PT-141 (Bremelanotide) include uncontrolled hypertension and cardiovascular disease. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for PT-141 (Bremelanotide) is limited.
Documented caution flags for PT-141 (Bremelanotide)
- Uncontrolled hypertension
- Cardiovascular disease
- Personal history of melanoma
Reported side effects to weigh
- Nausea (most common, severe in first uses)
- Facial flushing
- Headache
- Transient blood pressure increase
References
- Bremelanotide for HSDD in premenopausal women — Kingsberg SA et al., Obstet Gynecol, 2019
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide — Simon JA, Kingsberg SA, Portman D, et al.; Journal of Women's Health; 2022
- Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide — Althof S, Derogatis LR, Greenberg S, et al.; Journal of Sexual Medicine; 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PT-141 (Bremelanotide)
Full PT-141 (Bremelanotide) breakdownPT-141 (Bremelanotide) what it's used forPT-141 (Bremelanotide) side effectsPT-141 (Bremelanotide) how to take itPT-141 (Bremelanotide) mistakes to avoidPT-141 (Bremelanotide) half-lifePT-141 (Bremelanotide) how long to workPT-141 (Bremelanotide) legal statusPT-141 (Bremelanotide) how it workspt 141 vs kisspeptinAsk the AI Coach
Last updated 2026-06-15.